Condition: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Italian multicenter study, will enroll \~566 pts with oligometastatic hormone sensitive prostate cancer who are candidates to receive treatment with apalutamide. After 6 months from the start of treatment, patients will be randomized to receive local treatment based on the investigator's choice ( either one between primary radiotherapy or cytoreductive prostatectomy), in addition to apalutamide, or to continue just with medical therapy.
This description comes directly from the study's public registry record.
Valentina Guadalupi, MD · 00390223903811 · valentina.guadalupi@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| European Institute of Oncology | Milan, Lombardy, Italy | Not Yet Recruiting |
| ASST Santi Paolo e Carlo | Milan, Lombardy, Italy | Not Yet Recruiting |
| Istituto Tumori Milano | Milan, Mi, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05649943